These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35751566)

  • 21. The need for broadly protective COVID-19 vaccines: Beyond S-only approaches.
    Poland GA; Ovsyannikova IG; Kennedy RB
    Vaccine; 2021 Jul; 39(31):4239-4241. PubMed ID: 34167836
    [No Abstract]   [Full Text] [Related]  

  • 22. Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study.
    Hua Q; Zhang H; Yao P; Xu N; Sun Y; Lu H; Xu F; Liao Y; Yang J; Mao H; Zhang Y; Zhu H; Hu X; Lv H; Jiang J
    Front Immunol; 2022; 13():939311. PubMed ID: 36032136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First computational design using lambda-superstrings and in vivo validation of SARS-CoV-2 vaccine.
    Martínez L; Malaina I; Salcines-Cuevas D; Terán-Navarro H; Zeoli A; Alonso S; M De la Fuente I; Gonzalez-Lopez E; Ocejo-Vinyals JG; Gozalo-Margüello M; Calvo-Montes J; Alvarez-Dominguez C
    Sci Rep; 2022 Apr; 12(1):6410. PubMed ID: 35440789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2.
    Lin L; Ting S; Yufei H; Wendong L; Yubo F; Jing Z
    Virus Res; 2020 Oct; 288():198082. PubMed ID: 32621841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges.
    Dhama K; Dhawan M; Tiwari R; Emran TB; Mitra S; Rabaan AA; Alhumaid S; Alawi ZA; Al Mutair A
    Hum Vaccin Immunother; 2022 Nov; 18(5):2045853. PubMed ID: 35258416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Humoral and adaptive immune responses to the SARS-CoV-2 vaccine.
    Rizzo R; Bortolotti D; Morandi L; Rizzo S; Schiuma G; Beltrami S; Papi A; Contoli M
    Int J Infect Dis; 2022 Sep; 122():412-414. PubMed ID: 35750264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Scrutinizing the SARS-CoV-2 protein information for designing an effective vaccine encompassing both the T-cell and B-cell epitopes.
    Jain N; Shankar U; Majee P; Kumar A
    Infect Genet Evol; 2021 Jan; 87():104648. PubMed ID: 33264668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2022; 13():995235. PubMed ID: 36172368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses.
    Almendro-Vázquez P; Chivite-Lacaba M; Utrero-Rico A; González-Cuadrado C; Laguna-Goya R; Moreno-Batanero M; Sánchez-Paz L; Luczkowiak J; Labiod N; Folgueira MD; Delgado R; Paz-Artal E
    Front Immunol; 2022; 13():981350. PubMed ID: 36059485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
    Yu J; Tostanoski LH; Peter L; Mercado NB; McMahan K; Mahrokhian SH; Nkolola JP; Liu J; Li Z; Chandrashekar A; Martinez DR; Loos C; Atyeo C; Fischinger S; Burke JS; Slein MD; Chen Y; Zuiani A; Lelis FJN; Travers M; Habibi S; Pessaint L; Van Ry A; Blade K; Brown R; Cook A; Finneyfrock B; Dodson A; Teow E; Velasco J; Zahn R; Wegmann F; Bondzie EA; Dagotto G; Gebre MS; He X; Jacob-Dolan C; Kirilova M; Kordana N; Lin Z; Maxfield LF; Nampanya F; Nityanandam R; Ventura JD; Wan H; Cai Y; Chen B; Schmidt AG; Wesemann DR; Baric RS; Alter G; Andersen H; Lewis MG; Barouch DH
    Science; 2020 Aug; 369(6505):806-811. PubMed ID: 32434945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The SARS-CoV-2 spike residues 616/644 and 1138/1169 delineate two antibody epitopes in COVID-19 mRNA COMINARTY vaccine (Pfizer/BioNTech).
    Andries J; Viranaicken W; Cordonin C; Herrscher C; Planesse C; Roquebert B; Lagrange-Xelot M; El-Kalamouni C; Meilhac O; Mavingui P; Couret D; Gadea G; Despres P
    Sci Rep; 2022 Apr; 12(1):5999. PubMed ID: 35397679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines.
    Ambrosino D; Han HH; Hu B; Liang J; Clemens R; Johnson M; Siber G; Goldblatt D
    J Infect Dis; 2022 Jan; 225(2):327-331. PubMed ID: 34888662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 Vaccines: Where Did We Stand at the End of 2023?
    Lundstrom K
    Viruses; 2024 Jan; 16(2):. PubMed ID: 38399979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants.
    Gattinger P; Kratzer B; Tulaeva I; Niespodziana K; Ohradanova-Repic A; Gebetsberger L; Borochova K; Garner-Spitzer E; Trapin D; Hofer G; Keller W; Baumgartner I; Tancevski I; Khaitov M; Karaulov A; Stockinger H; Wiedermann U; Pickl WF; Valenta R
    Allergy; 2022 Aug; 77(8):2431-2445. PubMed ID: 35357709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.